Filgrastim

Generic Name
Filgrastim
Brand Names
Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim
Drug Type
Biotech
Chemical Formula
-
CAS Number
121181-53-1
Unique Ingredient Identifier
PVI5M0M1GW
Background

Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G...

Indication

Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
...

Associated Conditions
Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia
Associated Therapies
Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy
Clinical Trials
Related News

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

First Posted Date
2004-02-11
Last Posted Date
2024-11-04
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
65
Registration Number
NCT00077285
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis

First Posted Date
2004-01-12
Last Posted Date
2020-09-17
Lead Sponsor
Boston Medical Center
Target Recruit Count
62
Registration Number
NCT00075621
Locations
🇺🇸

Cancer Research Center at Boston Medical Center, Boston, Massachusetts, United States

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

First Posted Date
2003-12-15
Last Posted Date
2018-12-31
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
442
Registration Number
NCT00074490
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease

Phase 2
Withdrawn
Conditions
Lymphoma
First Posted Date
2003-10-08
Last Posted Date
2017-11-29
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Registration Number
NCT00005998

Pegfilgrastim PBPC Mobilization Study

First Posted Date
2003-08-05
Last Posted Date
2008-02-28
Lead Sponsor
Amgen
Target Recruit Count
41
Registration Number
NCT00066092

Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors

First Posted Date
2003-06-06
Last Posted Date
2019-02-15
Lead Sponsor
Children's Oncology Group
Target Recruit Count
38
Registration Number
NCT00061893
Locations
🇺🇸

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

🇺🇸

Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

🇺🇸

Edwards Comprehensive Cancer Center at Cabell Huntington Hospital, Huntington, West Virginia, United States

and more 98 locations

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

First Posted Date
2003-05-02
Last Posted Date
2017-11-29
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
13
Registration Number
NCT00003926
Locations
🇺🇸

University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

Stem Cell Transplant to Treat Patients With Systemic Sclerosis

Phase 1
Completed
Conditions
Systemic Sclerosis
First Posted Date
2003-04-09
Last Posted Date
2020-01-18
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
24
Registration Number
NCT00058578
Locations
🇺🇸

The Methodist Hospital, Houston, Texas, United States

PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma

First Posted Date
2003-02-06
Last Posted Date
2012-09-11
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
50
Registration Number
NCT00054665
Locations
🇺🇸

Roswell Parck Cancer Institute, Buffalo, New York, United States

🇺🇸

National Cancer Institute (NCI), Bethesda, Maryland, United States

Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma

First Posted Date
2003-01-27
Last Posted Date
2013-06-27
Lead Sponsor
Radiation Therapy Oncology Group
Registration Number
NCT00017160
Locations
🇺🇸

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

🇺🇸

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

🇺🇸

Valley Hospital, Ridgewood, New Jersey, United States

and more 232 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy